Document:

ADVISORY AGREEMENT

 

This ADVISORY AGREEMENT (this “Agreement”),
is entered into effective as of January 1, 2014, by and between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the
“Company”), and Kathleen Mullinix (“Advisor”).

 

RECITALS

 

WHEREAS, Advisor has certain knowledge,
expertise, experience and reputation which the Company desires to avail itself; and

 

WHEREAS, upon the terms and subject to the
conditions of this Agreement, the Company desires to retain Advisor to provide certain advisory services to the Company, and Advisor
wishes to render such services.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the
foregoing recitals and the mutual promises and agreements herein contained, Advisor and the Company by this Agreement agree as
follows:

 

1.          Engagement.
The Company hereby agrees that, commencing on January 1, 2014 (the “Effective Date”), the Company shall engage
Advisor and Advisor hereby accepts such engagement with the Company, upon the terms and subject to the conditions hereinafter set
forth.

 

2.          Term.
The initial term of Advisor’s engagement under this Agreement (the “Initial Term”) shall commence on the
Effective Date and, subject to the provisions of Section 6, shall continue until December 31, 2014. The Initial Term and any subsequent
one year term (each a “Term”) shall automatically be extended on an annual basis unless a Notice of Intent to Terminate
is given by either party at least 90 days before the end of the applicable Term.

 

3.          Services.
Advisor shall advise on business development.

 

4.          No
Authority to Bind. Except as directed and authorized by the Chief Executive Officer of the Company in writing, Advisor shall
not execute or agree to any contract, agreement or instrument on behalf of the Company.

 

5.          Compensation.
The Company shall pay to Advisor the sum of $25,000 payable in two installments of $12,500 with the first installment payable on
January 31, 2014 and the second installment payable on July 1, 2014.

 

6.          Termination.
The Company may terminate this Agreement at any time “for cause” upon delivery of written notice to Advisor, in which
case such termination shall be effective immediately upon Advisor’s receipt of the written notice.

 

    	- 1 -

    	 

    

 

“Cause” shall mean:

 

		(a)	Advisor is convicted of, or pleas nolo contendere (no contest) to, any crime (whether or not involving the Company)
constituting a felony in the jurisdiction involved; or

 

		(b)	Advisor is in material breach of any provision of this Agreement or any other agreement with the Company, or willfully fails
to or refuses to comply with the lawful directives of the Chief Executive Officer or the Board in the performance of her duties
under this Agreement (other than a failure caused by temporary disability).

 

7.          Proprietary
Rights and Nondisclosure and Nonuse of Confidential Information.

 

7.1          It
is understood that during the term of this Agreement, Advisor may be exposed to information that is confidential and proprietary
to the Company. All such information (hereinafter “Lixte Confidential Information”), whether written or oral, tangible
or intangible, that is made available, disclosed, or otherwise made known to Advisor by the Company or its employees under this
Agreement shall be considered confidential and shall be considered the sole property of the Company. Lixte Confidential Information
shall be (a) marked as confidential, or (b) otherwise represented by the disclosing party as confidential either before or within
a reasonable time after its disclosure to the receiving party. This obligation of confidentiality shall remain in effect for a
period of five (5) years after the expiration or termination of this Agreement.

 

7.2          The
obligations of confidentiality set forth in Paragraph 7.1 shall not apply to any information that:

 

		(a)	is or hereafter becomes generally available to the public other than by reason of any default with respect to a confidentiality
obligation under this Agreement; or

 

		(b)	was already known to the recipient as evidenced by prior written documents in its possession; or

 

		(c)	is disclosed to the recipient by a third party who is not in default of any confidentiality obligation to the disclosing party
hereunder; or

 

		(d)	is developed by or on behalf of the receiving party, without reliance on confidential information received hereunder as evidenced
by written documents in its possession; or

 

		(e)	has been approved in writing by one party for publication by the other party; or

 

		(f)	is required to be disclosed in compliance with applicable laws or regulations.

 

    	- 2 -

    	 

    

 

8.          Nonsolicitation;
Nondisparagement. Advisor acknowledges that during the course of Advisor’s engagement by the Company, Advisor has and
will continue to have the opportunity to develop relationships with existing employees, clients, distributors, and prospective
clients, and other business associates of the Company, which relationships constitute goodwill of the Company and that the Company
would be irreparably damaged if Advisor were to take actions that would damage or misappropriate such goodwill. Advisor accordingly
agrees that during the period commencing on the Effective Date and ending on the first anniversary of the conclusion of the Term,
Advisor shall not, directly or indirectly, either for the benefit of Advisor or any other person, do any of the following:

 

		(a)	Solicit any employee of the Company to terminate her employment with the Company, or employ any such individual during her
employment with the Company and for a period of six months after such individual terminates her employment with the Company;

 

		(b)	Solicit any distributor or customer, or prospective distributor or customer, of the Company to terminate her relationship with
the Company, or accept any business from any such distributor or customer, or prospective distributor or customer, of the Company;
or

 

		(c)	Make any public statement, comment or remark that disparages the integrity or competence of a Company officer, director, employee,
or shareholder, that disparages any product or service of the Company, or that is reasonably likely to cause injury to the relationships
between the Company and any existing or prospective distributor, client, contractual counterparty, supplier, customer, employee,
consultant or other business associate of the Company. Likewise, the Company agrees that it shall not make any public statement,
comment or remark that disparages the integrity or competence of Advisor.

 

9.          Status
as Advisor.

 

9.1          Intention
of the Parties. It is mutually understood and agreed that Advisor, while performing all responsibilities under this Agreement,
is and shall at all times be, act, function, and perform all services and responsibilities in the legal capacity of an independent
contractor. It is mutually understood and agreed that no work, act, commission or omission of any act by Advisor or the Company
pursuant to the terms and conditions of this Agreement shall be construed to make or render Advisor an employee of the Company.
Furthermore, Advisor shall not, under any circumstances, hold herself out to be an employee of the Company.

 

9.2          Independent
Advisor to Control Performance. The Company shall have no right or authority to direct or control Advisor with respect to the
performance of Advisor’s duties under this Agreement, or with respect to any other matter, except as otherwise provided by
this Agreement. It is further understood that Advisor is free to contract with other companies to provide professional services,
as long as that service does not violate the provisions of Sections 7 or 8.

 

    	- 3 -

    	 

    

 

 

9.3          Expenses.
Except as provided in this Section 9.3, Advisor shall be fully responsible to pay any and all expenses and disbursements that she
incurs in the performance of any services or obligations covered by this Agreement. The Company shall, however, reimburse Advisor
for all actual and reasonable travel expenses incurred by Advisor when Advisor is traveling at the request of the Company in connection
with its duties; provided, that (i) Advisor shall not be entitled to reimbursement for any individual expenditure in excess
of $1,000, unless such expenditure shall have been pre-approved in writing by the Company’s Chief Executive Officer, and
(ii) Advisor shall not be entitled to reimbursement for a particular expenditure if Advisor does not submit to the Company sufficient
documentation evidencing such expenditure.

 

9.4          Taxes
and Benefit Programs. Advisor shall be liable and responsible to pay any and all taxes relating to all amounts paid to Advisor
hereunder. It is understood and agreed that because Advisor is not an employee of the Company, the Company shall not withhold any
taxes from amounts paid to Advisor. Advisor shall be fully and solely responsible to report income and expenses. Advisor acknowledges
that she is solely responsible for her own tax planning and that the Company has not provided Advisor with any tax advice regarding
the tax implications of this Agreement. It is also understood and agreed that Advisor shall not be eligible to participate in any
benefits or programs sponsored or financed by the Company for its employees.

 

		10.	Miscellaneous.

 

10.1Notices.
All notices, requests, demands and other communications required or permitted to be given hereunder shall be in writing and shall
be deemed to have been duly given upon receipt, if delivered personally, upon confirmation of receipt, if given by electronic facsimile
and on the third business day following mailing, if mailed first-class, postage prepaid, registered or certified mail addressed
as follows:

 

	 	If to the Company to:
	 	 
	 	
        Lixte, Inc.

        6 Tinker Lane

        East Setauket, New York 11733

        Attn: John Kovach, M.D.

	 	 
	 	
        Phone:(631) 751-2882

        Fax:(631) 982-5050

        Email: kovach1329@yahoo.com

	 	 
	 	If to Advisor:
	 	 
	 	
        1050 Fifth Avenue

        New York, New York 10028

        Phone:

        Fax:

        e-mail:

 

    	- 4 -

    	 

    

 

Any party may by notice given in accordance
with this Section 11.1 to the other parties designate another address or person for receipt of notices hereunder.

 

10.2          Entire
Agreement. This Agreement contains the entire agreement of the parties with respect to the subject matter hereof. This Agreement
may be amended, superceded, canceled, renewed or extended, and the terms hereof or thereof may be waived, only by a written instrument
signed by each of the parties hereto or thereto or, in the case of a waiver, by the party waiving compliance.

 

10.3          Attorneys’
Fees. If any legal action or arbitration arises under this Agreement, arises by reason of any asserted breach of it, or arises
between the parties and is related in any way to the subject matter of the Agreement, the prevailing party shall be entitled to
recover all costs and expenses, including reasonable attorneys’ fees, arbitration costs, investigative costs, reasonable
accounting fees and charges for experts.

 

10.4          Binding
Effect; Assignment. This Agreement shall be binding upon and inure to the benefit of the parties and their respective permitted
successors and permitted assigns. Neither this Agreement nor any of the rights hereunder may be assigned by any party, nor may
any party delegate any obligations hereunder or thereunder, without the written consent of the other party hereto or thereto; provided,
however, that the Company may assign its rights hereunder to any subsidiary or to any person or entity that acquires, directly
or indirectly, all or substantially all of the Company’s business (whether through acquisition of assets, stock or any other
means). Any non-permitted assignment or attempted assignment shall be void, ab initio. Nothing herein is intended or shall
be construed to give any person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision
contained herein, except as otherwise provided herein.

 

10.5          Counterparts.
This Agreement may be executed by the parties in separate counterparts, each of which when so executed and delivered shall be an
original, but all such counterparts shall together constitute one and the same instrument. Delivery of any counterpart signature
page of this Agreement, written communication or notice hereunder by facsimile shall be equally as effective as delivery of a manually
executed original of such counterpart signature page, communication or notice.

 

10.6          Further
Assurances. Each party hereto shall execute such documents and other papers and take such further actions as may be reasonably
required or desirable to carry out the provisions of this Agreement and the transactions contemplated hereby.

 

10.7          Agreement
Authorized. Advisor hereby represents and warrants that she is free to enter into this Agreement and that she is free to render
its services pursuant to this Agreement, and that Advisor is not subject to any obligation or restriction that would prevent him
from discharging her duties under this Agreement, and agrees to indemnify and hold harmless the Company from and with respect to
any liability, damages or costs, including attorneys’ fees, arising out of any breach by Advisor of this representation and
warranty.

 

10.8          Governing
Law. The validity, interpretation and construction of this Agreement and each part thereof will be governed by the laws of
the State of New York.

 

    	- 5 -

    	 

    

 

10.9          Entire
Agreement. This Agreement, and any other agreement explicitly mentioned herein, by and between the Company and Advisor, set
forth the entire agreement between the Company and Advisor with respect to the subject matter hereof, and supersedes any and all
prior agreements between the Company and Advisor, whether written or oral, relating to any or all matters covered by and contained
or otherwise dealt with in this Agreement. This Agreement does not constitute a commitment of the Company with regard to Advisor’s
engagement, express or implied, other than to the extent expressly provided for herein.

 

10.10       Survival
at Termination. The termination of this Agreement shall not affect the obligations to the parties hereunder which by the nature
thereof are intended to survive any such termination including, without limitation, the obligations of Advisor under Sections 7
and 8.

 

IN WITNESS WHEREOF, the parties hereto have
duly executed this Advisory Agreement as of the day and year first above written.

 

	 	LIXTE BIOTECHNOLOGY HOLDINGS, INC.
	 	 
	 	By:	 
	 	 	Name:     John Kovach
	 	 	Its:           President
	 	 	 
	 	 
	 	Kathleen Mullinix

 

    	- 6 -Execution Version

 

SECOND AMENDMENT TO THE

 

MERGER AND SHARE EXCHANGE AGREEMENT 

 

This Second Amendment
to the Merger and Share Exchange Agreement (this “Amendment”) is made and entered into as of March 20,
2014 by and among Infinity Cross Border Acquisition Corporation, a British Virgin Islands business company with limited
liability (the “Parent”), Glori Acquisition Corp., a Delaware corporation and wholly-owned subsidiary
of the Parent (the “Purchaser”), Glori Merger Subsidiary, Inc., a Delaware corporation and wholly-owned
subsidiary of the Purchaser (“Merger Sub”), Infinity-C.S.V.C. Management Ltd. in its capacity
as the representative as further described in the Agreement (as defined below) (the “INXB Representative”),
and Glori Energy Inc., a Delaware corporation (the “Company”). The Parent, the Purchaser, Merger
Sub, the INXB Representative and the Company are sometimes referred to herein individually as a “Party”
and, collectively, as the “Parties”. Capitalized terms used herein but not otherwise defined herein shall
have the respective meanings assigned to such terms in the Merger and Share Exchange Agreement, dated January 8, 2014, by and among
the Parties, as amended by the First Amendment to the Merger and Share Exchange Agreement, dated February 20, 2014, by and among
the Parties (as amended, the “Agreement”).

 

WITNESSETH:

 

A.           The
Parties have entered into the Agreement, which sets forth the Parties’ rights and obligations with respect to the Transactions;
and

 

B.           The
Parties desire to amend the Agreement to reflect the authorization by the Company of a new class of stock, designated Series C-2
Preferred, par value $0.0001 per share (the “Series C-2 Preferred Stock”), the entrance by the Company
into the Series C-2 Preferred Stock and Warrant Purchase Agreement, dated as of March 13, 2014 (the “Series C-2 Purchase
Agreement”), and the issuance by the Company of the Series C-2 Preferred Stock and the warrants to purchase shares
of the Series C-2 Preferred Stock pursuant to the Series C-2 Purchase Agreement (the “Series C-2 Issuance”).

 

NOW, THEREFORE, in consideration
of the premises set forth above, which are incorporated in this Amendment as if fully set forth below, and the representations,
warranties, covenants and agreements contained in this Amendment, and intending to be legally bound hereby, the Parties hereto
agree as follows:

 

Article
I

Amendments

 

1.1           Merger
Consideration Amendments. The Agreement is amended as follows.

 

(a)          Section
2.7 of the Agreement is amended so that the language reading “twenty-two million, nine hundred fifty-three thousand, four
hundred thirty-two (22,953,432)” is replaced with language reading “twenty-three million, five hundred eighty-four
thousand, five hundred fifty-seven (23,584,557)”.

 

    	1

    	 

    

  

(b)          Section
2.15 of the Agreement is amended so that the language reading “six hundred eight-eight thousand, six hundred and three (688,603)”
is replaced with language reading “seven hundred seven thousand, five hundred thirty-seven (707,537)”.

 

(c)          The
first sentence of Section 5.3(a) of the Agreement is amended to read as follows: “The authorized capital of the Company consists
of: (i) 100,000,000 shares of Company Common Stock, 3,295,771 shares of which are issued and outstanding; and (ii) 29,522,607 shares
of Company Preferred Stock, (A) 521,852 of which have been designated Company Series A Preferred Stock, 475,541 of which are issued
and outstanding, (B) 2,901,052 of which have been designated Company Series B Preferred Stock, 2,901,052 of which are issued and
outstanding, (C) 13,780,033 of which have been designated Company Series C Preferred Stock, 7,296,607 of which are issued and outstanding,
(D) 8,836,718 of which have been designated Company Series C-1 Preferred Stock, 4,308,645 of which are issued and outstanding,
and (E) 3,482,952 of which have been designated Company Series C-2 Preferred Stock, 1,842,028 of which are issued and outstanding.”

 

(d)          The
definition of Company Investor Agreement set forth in the Agreement is amended so that each reference to “Fourth” is
instead a reference to “Fifth” and each reference to “April 30, 2013” is instead a reference to “March
13, 2014”.

 

(e)          The
definition of Company Preferred Stock set forth in the Agreement to is amended include the phrase “, the Company Series
C-2 Preferred Stock” after the words “Company Series C Preferred Stock”.

 

(f)          The
following definition is added to Section 12.1 of the Agreement:

 

“Company
Series C-2 Preferred Stock” means the Series C-2 Preferred Stock, par value $0.0001 per share, of the Company.

 

1.2           Changes
to Exhibits. Exhibits A and B to the Agreement are replaced with Exhibits A and B to this Amendment.

 

Article
II

Consents and Waivers

 

2.1           Consent
of the Parent. By executing this Amendment, the Parent (a) consents to the amendment of the Organizational Documents of
the Company to reflect the authorization of the Series C-2 Preferred, (b) consents to the entrance by the Company into the
Series C-2 Purchase Agreement, (c) consents to the entrance by the Company into the amended and restated Company Investor
Agreement, (d) consents to the Series C-2 Issuance by the Company and each such consent constitutes a written consent as required
by Section 6.3 of the Agreement.

 

2.2           Waivers
by the Parent. The Parent hereby waives the failure by the Company to enter into Warrant Termination Agreements with holders
of Series C-2 warrants within ten (10) Business Days of execution of the Agreement as required by Section 6.18 of the Agreement;
provided, that the Parent does not waive its rights under any other provision of the Agreement with respect to the Warrant
Termination Agreements, including Section 8.3(m) of the Agreement.

 

    	2

    	 

    

  

Article
III

MISCELLANEOUS

 

3.1           Incorporation
by Reference. Sections 11.1 through 11.6 and Section 11.8 through 11.10 of the Agreement are hereby incorporated by reference
and apply to this Amendment as if all references to “Agreement” contained therein were instead references to “Amendment.”

 

3.2           Entire
Agreement. This Amendment, the Agreement, and the documents or instruments referred to herein or therein, including any exhibits
and schedules attached hereto or thereto, which exhibits and schedules are incorporated herein by reference, and the Confidentiality
Agreement embody the entire agreement and understanding of the Parties hereto in respect of the subject matter contained herein.
There are no restrictions, promises, representations, warranties, covenants or undertakings, other than those expressly set forth
or referred to herein or the documents or instruments referred to herein or therein or the Confidentiality Agreement, which collectively
supersede all prior agreements and the understandings among the Parties with respect to such subject matter. This Amendment may
only be amended pursuant to a written agreement signed by each of the Parties hereto.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK; SIGNATURE PAGE FOLLOWS]

 

    	3

    	 

    

 

IN WITNESS WHEREOF, each
Party hereto has caused this Amendment to be signed and delivered by its respective duly authorized officer as of the date first
above written.

 

	 	The Parent:
	 	 
	 	INFINITY CROSS BORDER ACQUISITION CORPORATION,
	 	a British Virgin Islands company
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 	 
	 	The Purchaser:
	 	 
	 	GLORI ACQUISITION CORP.,
	 	a Delaware corporation
	 	 
	 	By:	 
	 	 	Name:  Mark Chess
	 	 	Title: President
	 	 	 
	 	Merger Sub:
	 	 
	 	GLORI MERGER SUBSIDIARY, INC.,
	 	a Delaware corporation
	 	 
	 	By:	 
	 	 	Name:  Mark Chess
	 	 	Title:President
	 	 	 
	 	The INXB Representative:
	 	 
	 	INFINITY-C.S.V.C. MANAGEMENT LTD.,
	 	in its capacity hereunder as the INXB Representative
	 	 
	 	By:	 
	 	 	Name:  
	 	 	Title:
	 	 	 

[SIGNATURE
PAGE TO SECOND AMENDMENT TO THE MERGER AND SHARE EXCHANGE AGREEMENT]

 

    	 

    	 

    

 

	 	The Company:
	 	 
	 	GLORI ENERGY INC.,
	 	a Delaware corporation
	 	 
	 	By:	 
	 	 	Name:  Stuart Page
	 	 	Title:  President and Chief Executive Officer

 

[SIGNATURE PAGE TO SECOND AMENDMENT
TO THE MERGER AND SHARE EXCHANGE AGREEMENT]

 

    	 

    	 

    

 

EXHIBIT
A

  

Form
of Lock-Up Agreement

 

[See attached]

 

    	 

    	 

    

 

EXHIBIT
B

 

Form
of Registration Rights Agreement

 

[See attached]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]